Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Capital Expenditures: 2020-2024

Historic Capital Expenditures for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to $374,000.

  • Taysha Gene Therapies' Capital Expenditures rose 211.59% to $77,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $486,000, marking a year-over-year increase of 23.66%. This contributed to the annual value of $374,000 for FY2024, which is 90.33% down from last year.
  • According to the latest figures from FY2024, Taysha Gene Therapies' Capital Expenditures is $374,000, which was down 90.33% from $3.9 million recorded in FY2023.
  • Taysha Gene Therapies' Capital Expenditures' 5-year high stood at $20.6 million during FY2022, with a 5-year trough of $82,000 in FY2020.
  • In the last 3 years, Taysha Gene Therapies' Capital Expenditures had a median value of $3.9 million in 2023 and averaged $8.3 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first spiked by 18,563.41% in 2021, then slumped by 90.33% in 2024.
  • Yearly analysis of 5 years shows Taysha Gene Therapies' Capital Expenditures stood at $82,000 in 2020, then surged by 18,563.41% to $15.3 million in 2021, then spiked by 34.73% to $20.6 million in 2022, then crashed by 81.24% to $3.9 million in 2023, then plummeted by 90.33% to $374,000 in 2024.